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OBJECTIVE: To evaluate the prognostic significance of microvessel density and p53 expression in pancreatic
cancer.
METHODS: Between 2008 and 2012, 49 patients with pancreatic adenocarcinoma underwent resection with
curative intention. The resected specimens were immunohistochemically stained with anti-p53 and anti-CD34
antibodies. Microvessel density was assessed by counting vessels within ten areas of each tumoral section a
highpower microscope.
RESULTS: The microvessel density ranged from 21.2 to 54.2 vessels/mm2. Positive nuclear staining for p53 was
found in 20 patients (40.6%). The overall median survival rate after resection was 24.1 months and there were
no differences in survival rates related to microvessel density or p53 positivity. Microvessel density was
associated with tumor diameter greater than 3.0 cm and with R0 resection failure.
CONCLUSIONS: Microvessel density was associated with R1 resection and with larger tumors. p53 expression
was not correlated with intratumoral microvessel density in pancreatic adenocarcinoma.
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’ INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is an aggressive
carcinoma whose incidence and prevalence have steadily
increased over the years. As a result, PDA has become the
fourth most common cause of cancer-related death in
the western world (1). Pancreatic cancer is also the fourth
leading cause of cancer-related mortality in the United States,
and in Brazil, the five-year actuarial survival rate is 5% (2).
The annual death rate from the disease almost equals its
annual incidence due to the aggressive nature of the cancer
and the lack of effective means of screening for it during
its early, curable stage. Molecular markers and imaging
have not proven to be accurate modalities for screening
for pancreatic cancer. The diagnosis and management
of pancreatic cancer continues to be an overwhelming
challenge (3,4).
Surgical treatment of PDA is considered a gold standard
procedure as staging permits, but the large majority of
patients have tumors that are unresectable at the time of
diagnosis. Nevertheless, in the absence of credible alternative
cures, surgical resection remains the only option with any
potential for curing pancreatic adenocarcinoma, with overall
resectability rates ranging from 15% to 20% for all patients,
mortality rates ranging from 2 to 5% and total complication
rates ranging from 30 to 40% (5).
Angiogenesis is the formation of new blood vessels from a
pre-existing vascular network. During the prognostic state
of cancer, it has been suggested that oxygen must penetrate
200 mm from a blood vessel to support cell existence and that
neovascularization is mandatory for tumor cell survival (6).
Some studies (7,8) have correlated microvessel density
(MVD) to angiogenesis and the presence of metastasis in
the peripheral regions of pancreatic tumors. The p53 tumor
suppressor gene seems to regulate angiogenesis to some
extent, and p53 mutations have been reported as possible
markers for identifying precursor lesions with malignant
transformation potential.
The aim of the current study was to determine what type
of relationship exists between MVD and p53 expression
with respect to patient outcome following surgical treatment
of pancreatic adenocarcinoma. Furthermore, we assessed theDOI: 10.6061/clinics/2016(06)05
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correlation between clinicopathological features, MVD and
survival outcome in these patients.
’ SUBJECTS AND METHODS
This study was approved by the Research and Ethics
Committee of the Faculdade de Medicina da Universidade
de São Paulo. Forty-nine patients underwent duodeno-
pancreatectomy with lymphadenectomy and histologi-
cally proven pancreatic adenocarcinomas were selected.
All patients were surgically treated at the Department of
Digestive Surgery, São Paulo School of Medicine and did
not receive chemotherapy or anti-angiogenesis therapy
before surgery. All patients were followed up and data
were collected between 2008 and 2012. The cases included
22 males and 27 females, with a mean age of 58.3 years
(Table 1). Paraffin blocks containing fragments of tumor
and adjacent epithelia were sectioned, stained with
hematoxylin & eosin (H&E), and prepared for histological
analysis by light microscopy.
Immunohistochemical determination of
p53 expression
Paraffin-embedded tissues were used for immunohisto-
chemical analysis of p53 expression. First, sections (2-3 mm)
were mounted on microscope slides. Then, the sections were
deparaffinized in xylene at 60o C for 30 minutes, followed by
treatment with a graded series of alcohol and rehydration.
For the deparaffinization, the samples were incubated
with hydrogen peroxide in methanol for 20 min to block
endogenous peroxidase. The sections were microwaved
twice at 500 W for 5 min each time in 10 mmol/L sodium
citrate (pH 6.0). The sections were then incubated with
antibody against human p53 protein produced from the
K0680 clone (DAKO LSABs) and washed with phosphate-
buffered saline (PBS).
The slides were examined by investigators who were blinded
to the corresponding clinicopathologic data. p53 immunoreac-
tivity was assessed as positive only when tumors exhibited
intense nuclear staining and the reactivity was categorized as
either negative expression (less than 10% positive tumor cells) or
positive expression (at least 10% positive tumor cells).
Quantification of microvessel density
To quantify microvessel density (MVD) in sections stained
for CD34, entire tumor sections were scanned at low power
(40x magnification) to identify areas rich in microvessels,
which were then counted in ten randomized areas (Figure 1).
In each area, individual microvessels were counted under
high power (200x magnification) to obtain a vessel count for
a hundred randomized defined points. The average vessel
count in the 10 randomized areas was taken as the MVD. The
vessel count was considered significant when the reticulum
was in the same position as the stained endothelial cells.
Associations with clinicopathological factors
We next studied the associations between MVD and the
following clinicopathological factors: sex, age (52 years old),
staging, tumor size, histological type, vascular invasion,
margins and survival rates. We also assessed the relationship
between p53 expression and the same clinicopathological
factors. Finailly, we compared the associations identified for
MVD and p53.
Statistical methods
The univariate association between MVD and each
clinicopathological item was analyzed using chi-squared
tests and t-tests. To determine independent prognostic
factors, a generalized linear model was used. Kaplan-Meyer
and Log-Rank tests were applied to assess survival rate.
Po0.05 was considered statistically significant.
’ RESULTS
Of the 49 patients included in the study, forty-six had
cephalic pancreatic carcinoma (93.8%). Thirty-one patients
(63.2%) were at least stage IIB and 32 (65.3%) patients had
tumors that were pT3. Twenty-nine patients (59.2%) had
lymph node metastasis, 45 (91.8%) had perineural invasion
Table 1 - Demographic and clinicopathologic distributions.
Variable N %
Gender
Female 27 55.1%
Male 22 44.9%
Age
Mean = 58.3 (40–77 months)
T
1 5 10.2%
2 8 16.3%
3 32 65.3%
4 4 8.2%
N
Negative 20 40.8%
Positive 29 59.2%
Staging
IA 4 8.2%
IB 5 10.2%
IIA 9 18.4%
IIB 27 55.1%
III 4 8.2%
Perineural invasion
Absent 4 8.2%
Present 45 91.8%
Vascular invasion
Absent 23 46.9%
Present 26 53.1%
Size
Mean = 3.32 (1.5-6.5 cm)
o3.0 cm 18 36.7%
X3.0 cm 31 63.3%
Histological type
Well differentiated 23 46.9%
Moderately differentiated 19 38.8%
Undifferentiated 7 14.3%
Margins
Free 30 61.2%
Compromised 19 38.8%
Vascular resection
No 39 79.6%
Yes 10 20.4%
MVD
Mean
o46.2 28 57.1%
X46.2 21 42.9%
p53
Negative 29 59.2%
Positive 20 40.8%
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and 26 (53.1%) had vascular invasion. The average tumor
size was 3.36 cm (1.5 to 6.5 cm).
The mean MVD was 46.2 vessels/mm2, and this value was
markedly higher in tumors equal to or greater than 3.0 cm in
diameter (p=0.03) (Table 2).
Table 3 shows the relationships that were identified
between p53 and clinicopathological factors; however, no
correlations were found.
The generalized linear model analysis of the assessed
clinicopathological factors revealed that surgical margin was
the only independent factor related to DMV (po0.05).
The actuarial survival rate did not demonstrate any
statistically significant differences when compared to the
MVD (p=0.69) (Figure 2).
’ DISCUSSION
In 1971, Folkman formulated the hypothesis that angiogen-
esis in tumor specimens can be determined by the numbers
and structures of blood vessels associated with a tumor and
depends on neovascularization, which it is closely associated
with tumor growth, staging and prognosis (9,10). In the same
way, knowledge regarding the biomolecular mechanisms
underlying angiogenesis has enabled efficient inhibition of
this process using anti-angiogenic molecules.
Several studies demonstrated that angiogenesis precedes
tumor progression and depends on a switch from a pre-
vascular to a vascular phase. Recent works have shown that
angiogenic factors are already expressed by pre-invasive
Figure 1 - Vessel counting using reticulum identification.
Table 2 - Relationships between microvessel density and clinicopathological features.
No. patients Mean MVD p
Total 49 46.2
Age
o52 years 14 (28.6%) 47.9±16.9 0.62
X52 years 35 (71.4%) 45.0±21.5
Gender
Male 22(44.9%) 45.1±19.2 0.71
Female 27(45.1%) 47.1±17.2
T
T1-2 13 (26.5%) 49.4±19.8 0.41
T3-4 36 (73.5%) 44.7±17.6
N
Negative 20 (40.8%) 47.3±17.6 0.18
Positive 29 (59.2%) 45.2±18.9
Size
o3.0 cm 20 (40.8%) 39.2±13.3 0.03
X3.0 cm 29 (59.2%) 50.4±19.8
Histological type
Well and moderately differentiated 42 (85.7%) 44.7±17.2 0.05
Undifferentiated 7 (14.3%) 55.3±12.5
p53
Negative 29 (59.2%) 44.0±14.7 0.39
Positive 20 (40.8%) 48.9±22.3
Vascular invasion
Absent 23 (46.9%) 46.1±18.3 0.99
Present 26 (53.1%) 46.2±18.4
Margins
Free 30 (61.2%) 42.5±15.6 0.04
Compromised 19 (39.8%) 53.3±20.1
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lesions and the induction of angiogenesis is completed
during the transition from hyperplasia to neoplasia. This
phenomenon is important for invasive cancer screening in
high-risk patients. Angiogenesis is also an important aspect
of drug delivery for several tumor types (11,12).
Our study indicated that MVD is not correlated with survival
prognosis in PDA, a finding that is concordant with results
reported by Ellis et al. (13) and Karademir et al. (14). This result
likely arose because of the absence of patient selection criteria
and the different methodological methods applied (e.g., for
vessel counting; Table 4), resulting in diverse MVD values.
In contrast, late diagnosis of tumors and the use of surgical
treatment have resulted in advanced staging of PDA. These
processes allowed a large number of microvessels to be
Table 3 - Relationships between p53 expression and clinicopathological factors (no correlations were found).
p53 negative p53 positive p
Age
o52 years 7 7 0.52
X52 years 22 13
Gender
Male 12 15 0.04
Female 17 5
T
T1-2 9 4 0.21
T3-4 20 16
N
Negative 11 9 0.77
Positive 18 11
Size
o3.0 cm 11 9 0.77
X3.0 cm 18 11
Histological type Well and moderately differentiated 24 18 0.41
Undifferentiated 5 2
Vascular invasion
Absent 14 9 1.0
Present 15 11
Margins
Free 19 11 0.55
Compromised 10 9
Figure 2 - Relationship between overall survival (months) and microvessel density.
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identified during tumor analysis and this MVD could not be
differentiated between groups. Kuehn et al. (15) demonstrated
that a correlation exists between MVD and prognosis; however,
over 60% of the patients studied were stage I and therefore had
sparser MVD compared to those with advanced tumors.
The p53 tumor suppressor gene is the most frequently
mutated gene in human cancer. p53 mutations play a role in
determining tumor sensitivity to apoptosis-inducing treat-
ments, such as radiation or cytotoxic drugs (16,17). p53 protein
has various important functions in cellular integration,
including cell growth control, response to DNA damage, cell-
cycle checkpoint control, regulation of transcription and
control of genomic stability. It has been suggested that p53
protein may play a role in suppressing angiogenesis (18).
However, in our study, no relationship was identified between
p53 and MVD or clinicopathological factors. Overall, MVD
analysis can be a useful tool for patient selection when
studying angiogenesis inhibition (12,19).
In conclusion, our results demonstrate that MVD is higher
in tumors greater than 3.0 cm in diameter and in cases with
involved margins. Furthermore, no relationship was found
to exist between p53 expression and tumor angiogenesis,
MVD or survival rates. Finally, neither MVD nor p53
expression could predict survival in patients with pancreatic
adenocarcinoma. There was also no correlation between p53
expression and intratumoral MVD. Finally, MVD analysis is
useful for predicting margin involvement.
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Table 4 - Different methods used to count vessels.
Author Year Number of patients Antibody Number of areas Type of count MVD (vessels/mm2)
Present study 2008 49 CD34 10 Weidner 46.2
Takagi 2008 41 CD34
CD45
Factor VIII
3 Lu´mem
Esposito 2004 137 CD34 5 Weidner 101*
Nakagawa 2002 32 CD34 5 Weidner
Niedergethmann 2002 70 CD34 5 Weidner 85*
Karademir 2000 22 Factor VIII 3 Weidner 3.4#
Ikeda 1999 40 CD34 6 Weidner
Fujimoto 1998 50 CD34 4 Weidner 30.1
Ellis 1998 22 Factor VIII - Weidner 44.9
*Only evaluated hypervascularized areas of neoplasm.
#Vessels/mm2/mm3 – vessels/mm.
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